A dual-transformable MgGa-MOF nanoplatform for HCC therapy via lactate metabolism blockade and immune reactivation - PubMed
6 hours ago
- #Lactate Metabolism
- #Microwave Therapy
- #Hepatocellular Carcinoma
- Dual-transformable MgGa-MOF nanoplatform (DMGTF NCs) developed for HCC therapy by blocking lactate metabolism and reactivating immunity post-MWA.
- Microwave ablation (MWA) is limited by lactate accumulation, which fuels residual tumor cells, acidifies TME, and impairs immune function, leading to recurrence/metastasis.
- DMGTF NCs release diclofenac sodium (Dis) upon microwave irradiation, suppressing MCT4-mediated lactate efflux to disrupt energy supply and reshape TME.
- Microwave-activated DMGTF generates ROS to impair mitochondrial lactate oxidation, increasing intracellular lactate accumulation and inducing metabolic stress.
- Framework-derived Mg²⁺ reactivates T cells, boosting proliferation and IFN-γ secretion, converting immunosuppressive pressure into antitumor power.
- Combination of DMGTF NCs with MWA achieves excellent therapeutic effects in HCC and lung metastasis models, addressing post-MWA relapse challenges.